Expansion of Regulatory T Cells Via IL-2/anti-IL-2 MAb Complexes Suppresses Experimental Myasthenia

Overview

Journal Eur J Immunol

Specialty Allergy & Immunology

Date 2010 Mar 31

PMID 20352624

Citations 54

Authors

Ruolan Liu

Qinghua Zhou

Antonio La Cava

Denise I Campagnolo

Luc Van Kaer

Fu-Dong Shi

Affiliations

Soon will be listed here.

Abstract

Human autoimmune diseases are often characterized by a relative deficiency in CD4(+)CD25(+) regulatory T cells (Treg). We therefore hypothesized that expansion of Treg can ameliorate autoimmune pathology. We tested this hypothesis in an experimental model for autoimmune myasthenia gravis (MG), a B-cell-mediated disease characterized by auto-Ab directed against the acetylcholine receptor within neuromuscular junctions. We showed that injection of immune complexes composed of the cytokine IL-2 and anti-IL-2 mAb (JES6-1A12) induced an effective and sustained expansion of Treg, via peripheral proliferation of CD4(+)CD25(+)Foxp3(+) cells and peripheral conversion of CD4(+)CD25(-)Foxp3(-) cells. The expanded Treg potently suppressed autoreactive T- and B-cell responses to acetylcholine receptor and attenuated the muscular weakness that is characteristic of MG. Thus, IL-2/anti-IL-2 mAb complexes can expand functional Treg in vivo, providing a potential clinical application of this modality for treatment of MG and other autoimmune disorders.

Citing Articles

Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis.

Wang F, Mei X, Yang Y, Zhang H, Li Z, Zhu L Front Mol Biosci. 2024; 11:1388476.

PMID: 39318549 PMC: 11420011. DOI: 10.3389/fmolb.2024.1388476.

A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells.

Lin Y, Wang X, Qin Y, Wang C, Zhou T, Zhang L Commun Biol. 2024; 7(1):299.

PMID: 38461332 PMC: 10925001. DOI: 10.1038/s42003-024-05987-z.

ILC2-mediated immune crosstalk in chronic (vascular) inflammation.

Kral M, van der Vorst E, Surnov A, Weber C, Doring Y Front Immunol. 2024; 14:1326440.

PMID: 38179045 PMC: 10765502. DOI: 10.3389/fimmu.2023.1326440.

Regulatory T lymphocytes in traumatic brain injury.

Shan J, Shi R, Hazra R, Hu X Neurochem Int. 2023; 173:105660.

PMID: 38151109 PMC: 10872294. DOI: 10.1016/j.neuint.2023.105660.

Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.

Tomasovic L, Liu K, VanDyke D, Fabilane C, Spangler J BioDrugs. 2023; 38(2):227-248.

PMID: 37999893 PMC: 10947368. DOI: 10.1007/s40259-023-00635-0.

References

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

La Cava A, Van Kaer L, Fu-Dong-Shi . CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol. 2006; 27(7):322-7. DOI: 10.1016/j.it.2006.05.003. View

Li X, Xiao B, Xi J, Lu C, Lu J . Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol. 2007; 126(2):180-8. DOI: 10.1016/j.clim.2007.10.001. View

Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen T . Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med. 2007; 13(4):423-31. PMC: 3427780. DOI: 10.1038/nm1564. View

Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M . IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol. 2006; 177(1):306-14. DOI: 10.4049/jimmunol.177.1.306. View

Hori S, Nomura T, Sakaguchi S . Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061. J Immunol. 2017; 198(3):981-985. View

Tang Q, Adams J, Penaranda C, Melli K, Piaggio E, Sgouroudis E . Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008; 28(5):687-97. PMC: 2394854. DOI: 10.1016/j.immuni.2008.03.016. View

Boyman O, Surh C, Sprent J . Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther. 2007; 6(12):1323-31. DOI: 10.1517/14712598.6.12.1323. View

Kamimura D, Bevan M . Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med. 2007; 204(8):1803-12. PMC: 2118678. DOI: 10.1084/jem.20070543. View

10.

Marie J, Letterio J, Gavin M, Rudensky A . TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005; 201(7):1061-7. PMC: 2213134. DOI: 10.1084/jem.20042276. View

11.

Fontenot J, Rasmussen J, Williams L, Dooley J, Farr A, Rudensky A . Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005; 22(3):329-41. DOI: 10.1016/j.immuni.2005.01.016. View

12.

Fattorossi A, Battaglia A, Buzzonetti A, Ciaraffa F, Scambia G, Evoli A . Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology. 2005; 116(1):134-41. PMC: 1802400. DOI: 10.1111/j.1365-2567.2005.02220.x. View

13.

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

14.

Sun Y, Qiao J, Lu C, Zhao C, Zhu X, Xiao B . Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy. Clin Immunol. 2004; 112(3):284-9. DOI: 10.1016/j.clim.2004.04.005. View

15.

Finkelman F, Madden K, Morris S, Holmes J, Boiani N, Katona I . Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993; 151(3):1235-44. View

16.

Luther C, Poeschel S, Varga M, Melms A, Tolosa E . Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol. 2005; 164(1-2):124-8. DOI: 10.1016/j.jneuroim.2005.03.011. View

17.

Sakaguchi S . Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6(4):345-52. DOI: 10.1038/ni1178. View

18.

Shevach E . CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002; 2(6):389-400. DOI: 10.1038/nri821. View

19.

Mostbock S, Lutsiak M, Milenic D, Baidoo K, Schlom J, Sabzevari H . IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells. J Immunol. 2008; 180(7):5118-29. DOI: 10.4049/jimmunol.180.7.5118. View

20.

Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S . Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2004; 105(2):735-41. PMC: 1847365. DOI: 10.1182/blood-2003-11-3900. View